Latest news articles

Added 1 month ago Drug news

EMA and Health Canada accept marketing applications for SHP 643 for the prevention of angioedema attacks .- Shire plc.

Shire plc announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for lanadelumab (SHP 643)...

Added 2 months ago Drug news

Phase III HELP study data on SHP 643 shows significant reduction of attacks in hereditary angioedema.- Shire.

Shire announced new Phase III results from the HELP Study, a global, multi-center, randomized, double-blind placebo-controlled parallel group trial that...

Added 3 months ago Drug news

FDA accepts BLA for SHP 643 to treat hereditary angioedema

Shire plc announced the FDA accepted the Biologics License Application (BLA) and granted priority review for lanadelumab (SHP 643). Lanadelumab...

Search all news articles for Immunity disorders

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Load more


ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...

Added 5 years ago

Search all guidelines for Immunity disorders

Journal articles

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...

Added 2 months ago

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.

Added 11 months ago

Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders

Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...

Added 3 years ago

Search all journal articles for Immunity disorders